CRBP

SEC source: 0000950170-24-075071 · ownership.xml · derivative · entry 18

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,667

Underlying: Common Stock · 9,333 shares

Expires 2024-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

F8 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 8

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,400

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 7

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 6

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,400

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 5

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-073710 · ownership.xml · derivative · entry 2

HOLMER ALAN F · CIK 0001329585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,667 shares

Expires 2024-07-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

F2 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

SEC source: 0000950170-24-073710 · ownership.xml · nonDerivative · entry 1

HOLMER ALAN F · CIK 0001329585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-075075 · ownership.xml · derivative · entry 10

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,367

Underlying: Common Stock · 7,788 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

SEC source: 0000950170-24-075075 · ownership.xml · derivative · entry 9

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,958

Underlying: Common Stock · 1,567 shares

Expires 2024-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

F6 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 4

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,605

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 3

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,605

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075075 · ownership.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · derivative · entry 17

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,831

Underlying: Common Stock · 12,487 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

SEC source: 0000950170-24-075071 · ownership.xml · derivative · entry 16

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,827

Underlying: Common Stock · 16,830 shares

Expires 2032-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 4

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,400

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 3

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,887

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 2

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,400

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-075071 · ownership.xml · nonDerivative · entry 1

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,230

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.

SEC source: 0000950170-24-068013 · ownership.xml · nonDerivative · entry 1

Ben Yong · CIK 0001967669 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-068039 · ownership.xml · nonDerivative · entry 1

Jenkins John Kenneth · CIK 0001742557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,816

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F2 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-068035 · ownership.xml · nonDerivative · entry 1

CATLIN AVERY W · CIK 0001255348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,350

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F2 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-068009 · ownership.xml · nonDerivative · entry 1

HOLMER ALAN F · CIK 0001329585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,162

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F2 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-068030 · ownership.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-068014 · ownership.xml · nonDerivative · entry 1

Jacques Rachelle Suzanne · CIK 0001772610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0000950170-24-068005 · ownership.xml · nonDerivative · entry 1

Altmeyer Anne · CIK 0001947086 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005671 · doc4.xml · derivative · entry 1

Ben Yong · CIK 0001967669 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005675 · doc4.xml · derivative · entry 1

Jenkins John Kenneth · CIK 0001742557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005672 · doc4.xml · derivative · entry 1

CATLIN AVERY W · CIK 0001255348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005673 · doc4.xml · derivative · entry 1

HOLMER ALAN F · CIK 0001329585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005674 · doc4.xml · derivative · entry 1

Jacques Rachelle Suzanne · CIK 0001772610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005676 · doc4.xml · derivative · entry 1

Salzmann Peter · CIK 0001796309 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005670 · doc4.xml · derivative · entry 1

Altmeyer Anne · CIK 0001947086 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,783

Underlying: Common Stock · 2,783 shares

Expires 2034-05-16

F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

SEC source: 0001209191-24-005284 · doc4.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,787 shares

Expires 2024-04-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-24-005284 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This amount includes 40,176 unvested restricted stock units ("RSUs") that were granted on February 12, 2024, which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 12, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated, shall be forfeited upon termination of service.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 10

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,025,000

F11 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $45.88 to $46.00 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 9

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,016,138

F10 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $44.84 to $45.72 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 8

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,859,541

F9 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $44.20 to $44.82 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 7

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,797,873

F8 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $43.15 to $43.82 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 6

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,779,325

F7 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $42.24 to $42.48 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 5

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,754,342

F6 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $40.83 to $41.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 4

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,725,000

F5 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $40.53 to $41.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 3

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,622,860

F4 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $39.55 to $40.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 2

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,532,535

F3 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $38.77 to $39.53 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund.

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-000985 · form4.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,521,799

F1 · price: Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $37.53 to $38.00 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below).

F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001209191-24-004120 · doc4.xml · derivative · entry 2

Smethurst Dominic · CIK 0001820549 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-02-27

F2 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 27, 2025, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 27, 2025.

SEC source: 0001209191-24-004120 · doc4.xml · nonDerivative · entry 1

Smethurst Dominic · CIK 0001820549 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: On February 27, 2024, the Reporting Person was granted 50,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 27, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

SEC source: 0001209191-24-003337 · doc4.xml · derivative · entry 2

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,176

Underlying: Common Stock · 40,176 shares

Expires 2034-02-12

F2 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 12, 2025, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 12, 2025.

SEC source: 0001209191-24-003337 · doc4.xml · nonDerivative · entry 1

Moran Sean F. · CIK 0001451495 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,818

F1 · shares: On February 12, 2024, the Reporting Person was granted 40,176 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001.25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 12, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

SEC source: 0001209191-24-003336 · doc4.xml · derivative · entry 2

Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,947

Underlying: Common Stock · 73,947 shares

Expires 2034-02-12

F2 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 12, 2025, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 12, 2025.